Trichotillomania and Neurodevelopmental Links

Overview

Trichotillomania (TTM) is a body-focused repetitive behaviour (BFRB) characterised by recurrent, compulsive hair pulling resulting in hair loss. Anthony's onset at age 12 (puberty) and 25-year history places this within a neurodevelopmental-endocrine framework, not simply "bad habit" or OCD.

Classification and Reclassification

Not Simply OCD

DSM-5 classifies TTM under "Obsessive-Compulsive and Related Disorders" but distinct from OCD proper
TTM lacks the classic obsessive thought → compulsive action cycle of OCD
BFRBs are increasingly understood as a separate category with different neurobiology
The BFRB spectrum includes: trichotillomania, excoriation (skin picking), onychophagia (nail biting), cheek chewing

Neuroimaging Differences from OCD

MRI studies show people with TTM have increased grey matter and decreased cerebellar volume compared to controls — a pattern not seen in OCD. Caudate nucleus abnormalities characteristic of OCD are not found in TTM. (Chamberlain SR et al. Br J Psychiatry 2008;193(3):216-221. PMID: 18757980)

A Neurodevelopmental Condition?

Growing evidence suggests TTM should be understood as neurodevelopmental:

Typical onset at late childhood/early adolescence (puberty)
High comorbidity with ADHD and autism
Involves basal ganglia and cortico-striatal circuitry — same circuits implicated in ADHD and autism
Self-regulatory function rather than anxiety-driven compulsion
79% of people with TTM have one or more mental health comorbidities (anxiety, depression, OCD, PTSD, ADHD)

Links to ADHD

Dopamine and Understimulation

Individuals with ADHD have lower dopamine in the central nervous system
BFRBs can be seen as self-stimulating behaviour that provides temporary dopamine release
The "understimulation model": when internal arousal is too low, BFRBs provide sensory input to up-regulate the nervous system
When arousal is too high (overwhelm), BFRBs down-regulate — creating a bidirectional regulatory function

The Stimulus Regulation Model

Penzel's model defines BFRBs as efforts to regulate internal sensory imbalance:

Understimulated → BFRB provides sensory activation
Overstimulated → BFRB provides grounding/soothing
This maps directly onto ADHD's arousal dysregulation

Internal Hyperactivity Connection

Anthony's ADHD-PI with internal hyperactivity creates a specific risk profile:

Racing internal thoughts → need for grounding → hair pulling as tactile anchor
See ADHD-PI and Internal Hyperactivity for mechanism detail

Links to Autism

BFRBs vs Stimming

Feature	Stimming	BFRB
Purpose	Self-regulation, expression	Self-regulation
Harm	Usually non-damaging	Results in physical damage
Awareness	Variable	Often unaware during episodes
Control	Can be voluntary	Difficult to control
Distress	Usually not distressing	Distressing due to consequences

Prevalence of TTM in Autism

In a study of 112 children with ASD, the 3-month point prevalence of TTM was 3.9% — nearly twice the general population rate (Simonoff E et al. J Am Acad Child Adolesc Psychiatry 2008;47(8):921-929. PMID: 18645422)
24.7% of autistic subjects had comorbidity with Tourette syndrome, chronic tics, or trichotillomania (Canitano R, Vivanti G. Autism 2007;11(1):19-28. PMID: 17175571)
Autistic adults describe stimming as an important adaptive self-regulatory mechanism for managing intense emotions, sensory overload, and anxiety (Kapp SK et al. Autism 2019;23(7):1782-1792. PMC6728747)

Overlap

BFRBs may represent a form of dysregulated stimming — the same self-regulatory drive but with harmful execution
In undiagnosed autistic individuals, the absence of acceptable stim outlets may channel self-regulation into BFRBs
Sensory-seeking component: the tactile sensation of hair pulling may fulfil an unmet sensory need
Higher BFRB rates in autism than general population

Why CBT Failed

Anthony tried CBT for trich before knowing about his AuDHD. Standard Habit Reversal Training (HRT) often fails in neurodivergent populations because:

It ignores the regulatory function — simply replacing the behaviour doesn't address the underlying sensory/arousal need
Executive function demands — HRT requires self-monitoring and response inhibition, both compromised in ADHD
Doesn't account for masking fatigue — autistic people may lack cognitive resources for additional self-monitoring
No sensory alternative — standard competing responses may not match the sensory profile needed
CBT assumes neurotypical emotional processing — may not translate well to autistic internal experience

Puberty Onset — Why Age 12?

Hormonal Triggers

Puberty brings massive neurohormonal changes
Testosterone increases dopaminergic activity but also changes reward sensitivity
Cortisol axis maturation alters stress responses
The prefrontal cortex is still developing while hormonal drives increase — creating a regulatory gap
Lower progesterone was associated with more severe TTM symptoms in adolescent females; puberty hormones and stress hormones may trigger hair pulling in genetically predisposed individuals (Chamberlain SR et al. Psychiatry Res 2018;267:190-194. PMID: 29753253)
In adolescents, the prevalence of ADHD among TTM patients was 39.9% versus 19.9% in controls (Stein DJ et al. J Am Acad Child Adolesc Psychiatry 2023;62(10):S282-S283)

Neurodevelopmental Timing

Late childhood/early adolescence is when social demands escalate
For an undiagnosed autistic individual, social masking demands peak at this age
The increased cognitive load of masking + hormonal changes + ADHD executive dysfunction creates a perfect storm for BFRB emergence
Hair pulling may have emerged as an unconscious coping mechanism for an overwhelmed nervous system

Iron, Minerals, and Trichotillomania

Iron

Basal ganglia have the highest iron concentration in the brain
OCD-spectrum conditions show altered iron deposition in globus pallidi (decreased T2 relaxation values suggesting increased iron)
Anthony's iron overload (TSAT 60%) may contribute to basal ganglia dysfunction affecting cortico-striatal circuits
Hypothesis: excess iron in basal ganglia could disrupt the reward/habit circuitry that underlies BFRBs
NBIA disorders (genetic conditions causing brain iron accumulation in basal ganglia) feature prominent OCD, hyperactivity, impulsivity, vocal/motor tics, and compulsive behaviours — demonstrating the principle that excessive iron in basal ganglia drives compulsive behaviours (Gregory A, Hayflick SJ. GeneReviews. PMID: 20301750)
In C282Y/H63D compound heterozygotes, brain iron MRI measures show associations with altered iron distribution, though with smaller effect sizes than C282Y homozygotes (Atkins JL et al. J Alzheimers Dis 2021;79(3):1203-1211. PMC7990419)
Haemochromatosis patients are at greater risk of poor mental health; case reports document bipolar disorder, major depression, and psychosis that partially or completely resolved after phlebotomy

Zinc

Anthony's zinc is low-normal (12.5 umol/L, 12% into range)
Zinc is a cofactor for over 300 enzymes including those in neurotransmitter synthesis
Zinc deficiency is associated with impaired impulse control
Zinc modulates glutamate receptors (NMDA) — and the glutamate hypothesis is central to TTM

Vitamin D

TTM was significantly associated with vitamin D deficiency (OR 4.2)
Case reports show resolution of TTM symptoms with vitamin D3 supplementation over 3-4 months
Anthony's vitamin D status is untested — this should be checked
See Action Items and Monitoring Plan — vitamin D was already flagged as not yet tested

Neurobiology — The Glutamate Hypothesis

Central Role of Glutamate

TTM involves dysregulation of glutamatergic signalling in cortico-striatal-thalamic circuits
Excessive glutamate in the nucleus accumbens and striatum drives compulsive behaviours
The glutamate transporter system (particularly in astrocytes) is impaired
This creates an excitatory/inhibitory imbalance

The Cystine-Glutamate Antiporter (System Xc-)

System Xc- exchanges extracellular cystine for intracellular glutamate
In TTM, this system may be dysregulated → excess synaptic glutamate
NAC (N-acetylcysteine) targets this system directly — see treatment section

Iron's Role in Glutamate

Glutamate-cysteine ligase (the rate-limiting enzyme in glutathione synthesis) is iron-dependent
Iron overload may impair glutathione production → impaired glutamate clearance → excitotoxicity loop
This provides a mechanistic link between Anthony's iron overload and his trichotillomania

Genetics of Trichotillomania

Gene	Function	Relevance
SAPAP3 (DLGAP3)	Post-synaptic scaffold at glutamate synapses	Animal knockouts show compulsive grooming
SLITRK1	Neurite outgrowth in cortico-striatal circuits	Associated with TTM and Tourette's
SLC6A4	Serotonin transporter	Modulates serotonergic tone; BFRB associations
HoxB8	Expressed in microglia and cortico-striatal circuits	HoxB8 knockout mice show excessive grooming
SLC1A1	Neuronal glutamate transporter	OCD-spectrum associations
GRIN2B	NMDA receptor subunit	Glutamate signalling in reward/habit circuits

Evidence-Based Treatments

NAC (N-Acetylcysteine)

Mechanism: Restores cystine-glutamate antiporter function → reduces excess synaptic glutamate → normalises cortico-striatal signalling

Evidence:

Grant JE et al. Arch Gen Psychiatry 2009;66(7):756-763 — 56% of adults improved on NAC vs 16% on placebo in RCT (PMID: 19581567)
Typical dose: 1200-2400mg/day
Onset: 4-9 weeks for effect
Note: paediatric trial (Bloch MH et al. 2013) showed no benefit in children age 8-17 — the adult evidence is stronger

Additional Benefits for Anthony's Profile:

NAC is also a glutathione precursor → addresses oxidative stress from iron overload
NAC has evidence in autism for reducing irritability
NAC may improve mitochondrial function
Multi-target molecule hitting TTM, iron-related oxidative stress, and neuroinflammation

Inositol

Regulates serotonergic receptor signalling (phosphoinositide second messenger system)
Evidence in OCD: as effective as SSRIs in small studies (Fux M et al. 1996)
Anecdotal evidence in TTM at 18g/day doses
Mechanism distinct from NAC — targets serotonin rather than glutamate
Could potentially complement NAC

Memantine (Glutamate Confirmation)

RCT of memantine (another glutamate modulator) in 100 adults with TTM or skin-picking disorder: 60.5% improved on memantine vs. 8.3% on placebo (NNT=1.9), strongly supporting the glutamate hypothesis for BFRBs with a second agent
Grant JE et al. Am J Psychiatry 2023;180(5):348-356. PMID: 36856701 — already cited in Verified Citations section

Comprehensive Behavioural Treatment (ComB)

Addresses sensory, cognitive, affective, and motor factors individually rather than treating TTM as a unitary habit
35% clinical response in RCT (Falkenstein MJ et al. Behav Ther 2022;53(2):361-373. PMID: 34656205)

ACT-Enhanced Behaviour Therapy

Combines HRT with acceptance and commitment therapy to address emotional drivers and psychological inflexibility
Citation: Woods DW, Twohig MP. Trichotillomania: An ACT-enhanced Behavior Therapy Approach. Oxford University Press, 2008

Modified CBT/HRT for Neurodivergent People

Standard HRT should be adapted for AuDHD:
- Incorporate sensory alternatives that match the specific sensory profile
- Account for executive function limitations
- Address the underlying regulatory need, not just the behaviour
- Use external cues rather than relying on self-monitoring
- Consider fidget tools, textured objects, or other sensory substitutes

Stimulant Medication

Elvanse may partially help TTM by improving dopamine tone and reducing understimulation-driven pulling
Some individuals report reduced BFRBs on stimulant medication
Others report worsening (increased focus on the pulling sensation)
Effect is variable and should be monitored

Summary Model

flowchart TD
    A[ADHD-PI - Low dopamine] --> B[Understimulation / Dysregulation]
    C[Autism - Sensory needs] --> B
    D[HFE - Iron overload] --> E[Basal ganglia iron disruption]
    D --> F[Impaired glutathione / oxidative stress]
    E --> G[Cortico-striatal circuit dysfunction]
    F --> H[Excess synaptic glutamate]
    G --> I[Trichotillomania]
    H --> I
    B --> I
    J[Puberty hormones age 12] --> K[Regulatory gap]
    K --> I
    L[Decades of masking] --> M[Depleted coping resources]
    M --> I

Verified Academic Citations

Citations verified via PubMed and OpenAlex on 2026-03-22. Organised by topic area.

TTM-ADHD Comorbidity

Chesivoir EK, Valle S, Grant JE. Comorbid trichotillomania and attention-deficit hyperactivity disorder in adults. Compr Psychiatry. 2022;116:152317. PMID: 35512574 | DOI: 10.1016/j.comppsych.2022.152317
- Of 308 adults with TTM, 15.3% met clinical threshold for ADHD. Comorbid ADHD was associated with significantly higher impulsivity across all domains (attentional, motor, non-planning; all p < .0001). Stimulant medication for ADHD did not worsen TTM severity.
Grant JE, Chamberlain SR. Natural recovery in trichotillomania. Aust N Z J Psychiatry. 2022;56(10):1357-1362. PMID: 34903086 | DOI: 10.1177/00048674211066004
- Large epidemiological sample (n=10,169). 24.9% of people with lifetime TTM experienced natural recovery. Those who did not recover had significantly higher rates of comorbid ADHD, OCD, panic disorder, skin picking, and tics.
Golubchik P, Sever J, Weizman A, Zalsman G. Methylphenidate treatment in pediatric patients with ADHD and comorbid trichotillomania: a preliminary report. Clin Neuropharmacol. 2011;34(3):108-110. PMID: 21586916 | DOI: 10.1097/WNF.0b013e31821f4da9
- 9 children/adolescents with ADHD+TTM treated with methylphenidate for 12 weeks. ADHD symptoms improved significantly (p < .003), but hair pulling did not significantly change overall. Non-response of TTM to MPH was associated with higher stressful life event history.

TTM-Autism and Neurodevelopmental Links

Grant JE, Chamberlain SR. Autistic traits in trichotillomania. Brain Behav. 2022;12(7):e2663. PMID: 35674478 | DOI: 10.1002/brb3.2663
- 50 adults with DSM-5 TTM screened using the AQ-10. 14.6% scored at or above the ASD screening threshold (score >=6). Autism scores correlated with family dysfunction but not with TTM severity or impulsivity. Highlights need to screen for autistic traits in TTM.
Farhat LC, Isomura K, Fernandez de la Cruz L, et al. Sociodemographic and clinical characteristics of 1,234 individuals diagnosed with trichotillomania in the Swedish National Patient Register. Sci Rep. 2025;15:10396. PMID: 40140525 | DOI: 10.1038/s41598-025-95416-w
- Largest register-based TTM study (n=1,234). 79% had comorbid psychiatric disorders. Neurodevelopmental disorders (including ADHD) were present in 39% of TTM patients. Anxiety (65%), depression (48%), and NDDs (39%) were the three most common comorbidity categories.
Lin A, Farhat LC, Flores JM, et al. Characteristics of trichotillomania and excoriation disorder across the lifespan. Psychiatry Res. 2023;322:115120. PMID: 36842397 | DOI: 10.1016/j.psychres.2023.115120
- Cross-sectional survey of TTM and excoriation disorder (ages 4-67). ADHD rates ranged from 12-32% across groups. Severity peaked at the transition from adolescence to adulthood. Pulling/picking styles shifted across the lifespan.

NAC and Glutamate Modulation

Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2009;66(7):756-763. PMID: 19581567 | DOI: 10.1001/archgenpsychiatry.2009.60
- Landmark RCT (n=50, 12 weeks). 56% of NAC-treated adults were "much or very much improved" vs. 16% on placebo (p = .003). NAC dose 1200-2400 mg/day. Improvement first noted at 9 weeks. No adverse events in the NAC group.
Grant JE, Chesivoir E, Valle S, et al. Double-blind placebo-controlled study of memantine in trichotillomania and skin-picking disorder. Am J Psychiatry. 2023;180(5):348-356. PMID: 36856701 | DOI: 10.1176/appi.ajp.20220737
- RCT of memantine (another glutamate modulator) in 100 adults with TTM or skin-picking disorder. 60.5% improved on memantine vs. 8.3% on placebo (NNT=1.9). Supports the glutamate hypothesis for BFRBs with a second agent.
Lee DK, Lipner SR. The potential of N-acetylcysteine for treatment of trichotillomania, excoriation disorder, onychophagia, and onychotillomania: an updated literature review. Int J Environ Res Public Health. 2022;19(11):6370. PMID: 35681955 | DOI: 10.3390/ijerph19116370
- Updated review of 24 studies (RCTs, cohort studies, case reports) of NAC in BFRBs. NAC shows promise but evidence still derives from small trials. Larger, longer-duration studies are needed.
Goldin D, Salani DA, Valdes B. N-Acetylcysteine (NAC) for trichotillomania and excoriation disorder: an overview. J Psychosoc Nurs Ment Health Serv. 2026;64(1):15-23. PMID: 40359441 | DOI: 10.3928/02793695-20250506-04

Clinical overview of NAC's mechanism in BFRBs: maintains glutamate homeostasis in the brain, reducing compulsive and habitual behaviours. NAC is well-tolerated and accessible as a dietary supplement.

Hoffman J, Williams T, Rothbart R, et al. Pharmacotherapy for trichotillomania. Cochrane Database Syst Rev. 2021;9:CD007662. PMID: 34582562 | DOI: 10.1002/14651858.CD007662.pub3

Cochrane meta-analysis of 12 RCTs. Preliminary evidence supports NAC (RR 3.5 vs placebo in adults), clomipramine, and olanzapine. NAC showed no benefit in the child/adolescent trial. SSRIs showed no clear efficacy for TTM.

Deepmala, Slattery J, Kumar N, et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neurosci Biobehav Rev. 2015;55:294-321. PMID: 25957927 | DOI: 10.1016/j.neubiorev.2015.04.015

Systematic review finding favourable evidence for NAC in trichotillomania, autism, OCD, bipolar disorder, and depression. NAC targets oxidative stress, mitochondrial dysfunction, neuroinflammation, and glutamate/dopamine dysregulation.

SAPAP3/DLGAP3 and Compulsive Grooming Neurobiology

Soto JS, Jami-Alahmadi Y, Chacon J, et al. Astrocyte-neuron subproteomes and obsessive-compulsive disorder mechanisms. Nature. 2023;616(7958):764-773. PMID: 37046092 | DOI: 10.1038/s41586-023-05927-7

Discovered that SAPAP3 (DLGAP3) is expressed at high levels in striatal astrocytes, not just neurons. Both astrocytic and neuronal SAPAP3 contribute to OCD-like phenotypes in Sapap3 knockout mice. Implies astrocyte-targeted therapies may be relevant for compulsive grooming.

Soto JS, Neupane C, Kaur M, et al. Astrocyte Gi-GPCR signaling corrects compulsive-like grooming and anxiety-related behaviors in Sapap3 knockout mice. Neuron. 2024;112(20):3412-3423.e6. PMID: 39163865 | DOI: 10.1016/j.neuron.2024.07.019

Normalising striatal astrocyte morphology and function via Gi-GPCR chemogenetics corrected compulsive grooming in Sapap3 KO mice. Supports an astrocytic pharmacological strategy for compulsive behaviour disorders.

Piantadosi SC, Manning EE, Chamberlain BL, et al. Hyperactivity of indirect pathway-projecting spiny projection neurons promotes compulsive behavior. Nat Commun. 2024;15:4434. PMID: 38789416 | DOI: 10.1038/s41467-024-48331-z

Contrary to prevailing models, indirect pathway (not direct pathway) hyperactivity drove compulsive grooming in Sapap3 KO mice. Suppressing this pathway with optogenetics or fluoxetine reduced grooming.

Mondragon-Gonzalez SL, Schreiweis C, Burguiere E. Closed-loop recruitment of striatal interneurons prevents compulsive-like grooming behaviors. Nat Neurosci. 2024;27(6):1148-1156. PMID: 38693349 | DOI: 10.1038/s41593-024-01633-3

Real-time closed-loop optogenetic stimulation of striatal parvalbumin interneurons (triggered by OFC biomarkers) reduced compulsive grooming in Sapap3 KO mice to wild-type levels with 87% less stimulation time.

Gattuso JJ, Wilson C, Hannan AJ, Renoir T. Psilocybin reduces grooming in the SAPAP3 knockout mouse model of compulsive behaviour. Neuropharmacology. 2025;262:110202. PMID: 39489287 | DOI: 10.1016/j.neuropharm.2024.110202

Acute psilocybin (single dose) produced enduring reductions in compulsive grooming up to 1 week post-injection in Sapap3 KO mice, without affecting anxiety. Suggests serotonergic psychedelics as potential novel treatment.

TTM Genetics

Reid M, Lin A, Farhat LC, et al. The genetics of trichotillomania and excoriation disorder: a systematic review. Compr Psychiatry. 2024;133:152506. PMID: 38833896 | DOI: 10.1016/j.comppsych.2024.152506

Systematic review of 109 genetic studies. Genetic factors play an important role in TTM and excoriation disorder, some shared with OCD spectrum. No high-confidence specific risk genes identified yet. Calls for larger GWAS and whole-genome sequencing studies.

Halvorsen MW, Garrett ME, Cuccaro ML, et al. Genomic analysis of trichotillomania. Am J Med Genet B Neuropsychiatr Genet. 2025;198(7):120-125. PMID: 40511557 | DOI: 10.1002/ajmg.b.33035

First formal GWAS of TTM (101 cases vs. 488 controls). No genome-wide significant common variants found. TTM cases carried higher polygenic risk for psychiatric disorders (p = 0.008) and rare CNVs in neuropsychiatric genes (NRXN1, CSMD1, 15q11.2 deletions).

BFRB Neurobiology and Dopamine

Okumus HG, Akdemir D. Body focused repetitive behavior disorders: behavioral models and neurobiological mechanisms. Turk Psikiyatri Derg. 2023;34(1):50-59. PMID: 36970962 | DOI: 10.5080/u26213

Review of BFRB etiopathogenesis. Identified roles for glutamate and dopamine systems, cognitive flexibility and motor inhibition defects, and cortico-striato-thalamo-cortical circuit abnormalities in neuroimaging. BFRBs are inherited at a high rate.

TTM and Minerals/Vitamins

Parikh AK, Musolff N, Tchack M, Rao B. A case-control study of trichotillomania patients using a national database. Skin Appendage Disord. 2025;11(4):379-384. PMID: 40771450 | DOI: 10.1159/000543503

Case-control study (40 TTM vs. 400 controls) from the All of Us database. TTM was significantly associated with OCD (OR 18.3), borderline personality disorder (OR 15), anxiety (OR 10.2), depression (OR 5.89), ADHD, and vitamin D deficiency (OR 4.2) (all p < 0.01).

Akaltun I. Trichotillomania triggered by vitamin D deficiency and resolving dramatically with vitamin D therapy. Clin Neuropharmacol. 2019;42(1):20-21. PMID: 30649027 | DOI: 10.1097/WNF.0000000000000317

Case report: 4-year-old girl with TTM triggered by vitamin D deficiency. TTM resolved with vitamin D supplementation.

Titus-Lay E, Eid TJ, Kreys TJ, et al. Trichotillomania associated with a 25-hydroxy vitamin D deficiency: a case report. Ment Health Clin. 2020;10(1):38-43. PMID: 31942278 | DOI: 10.9740/mhc.2020.01.038

Two female patients with TTM and documented vitamin D deficiency. Supplementation with vitamin D3 1000 IU/day produced marked improvement over 3-4 months on the MGH Hair Pulling Scale, correlating with normalising serum 25(OH)D levels.

Kalyoncu T, Cildir DA, Ozbaran B. Trichotillomania in celiac disease patient refractory to iron replacement. Int J Adolesc Med Health. 2019;31(4). PMID: 28779566 | DOI: 10.1515/ijamh-2017-0027

Case of 11-year-old with celiac disease and TTM. TTM was more likely caused by behavioural disorders secondary to celiac disease rather than iron deficiency alone, illustrating the complex gut-brain-behaviour interplay.

Comprehensive Case-Control and Epidemiological

Silva B, Canas-Simiao H, Cavanna AE. Neuropsychiatric aspects of impulse control disorders. Psychiatr Clin North Am. 2020;43(2):249-262. PMID: 32439020 | DOI: 10.1016/j.psc.2020.02.001

Review noting that impulse control disorders (including TTM) play a significant role as comorbidities in neurodevelopmental disorders (ADHD, Tourette syndrome) and neurodegenerative disorders. Supports framing TTM within a neurodevelopmental context.